The adjuvanticities of GM-CSF-BMDC, FLT3L-BMDC and Mo-DC were statistically indistinguishable from each other (Fig. 1d); however, we consider GM-CSF BMDC to be the better adjuvants for two reasons: (1) the kinetics of tumor rejection seen in BMDC-immunized mice is clearly very different from that seen with Mo-DCs and FLT3L-DC. The gene discussed is CSF2; the disease is neoplasm.